March 13, 2018 / 10:46 PM / 6 months ago

BRIEF-Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook On Pulmonary Disease Pipeline

March 13 (Reuters) - Pulmatrix Inc:

* PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE

* PULMATRIX INC - PHASE 2A STUDY EXPECTED TO BEGIN IN Q4-2018 FOR PULMAZOLE

* PULMATRIX INC - EXPECT NON-CLINICAL SAFETY DATA ON PUR1800 IN SECOND HALF OF 2018

* PULMATRIX INC - FY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.93 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below